Skip to search formSkip to main contentSkip to account menu

anti-CD137 monoclonal antibody

Known as: Anti-4-1BB Monoclonal Antibody, Immunoglobulin G4, Anti-(Human Receptor 4-1BB) (Human Gamma-Chain), Disulfide with Human Kappa-Chain, Dimer, URELUMAB 
A fully human agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. Anti-CD137… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Background: Antibodies against several agonistic immunomodulatory receptors proved to be highly efficacious in preclinical tumor… 
2017
2017
e14626Background: Urelumab (BMS-663513) is a humanized monoclonal antibody binding to CD137 which, upon Fc-clustering, leads to… 
2017
2017
e14545Background: Tumor specific TILs can be in vitro expanded and have the ability to induce complete and durable tumor… 
2016
2016
ABSTRACT Studies of sequential anti-CD137/anti-CD20 therapy have previously shown that the efficacy of anti-CD20 was heavily… 
2014
2014
3017 Background: Anti-CD137 antibody was shown in both murine cancer models and in a first-in-human, phase I trial (Sznol et al… 
2014
2014
The past decade has been a period of tremendous progress in the area of cancer immunotherapy. The field has progressed from a… 
2013
2013
TPS3108 Background: CD137 (4-1BB) is a costimulatory molecule that belongs to the TNF superfamily. It is upregulated on activated… 
Highly Cited
2007
Highly Cited
2007
A rational monoclonal antibody (mAb)-based antitumor therapy approach has previously been shown to eradicate various established… 
Review
2006
Review
2006
It is perhaps rare to encounter among the various immunologically competent receptor–ligand pairs that a single cell surface…